5444
A. Dassonville et al. / Bioorg. Med. Chem. Lett. 14 (2004) 5441–5444
Table 2. Inhibition of the acute TPA-induced mouse ear swelling after
topical application of 3-indolylpropanamides
References and notes
1. Vernhet, L.; Petit, J. Y.; Lang, F. J. Pharmacol. Exp. Ther.
1997, 283, 358–365.
2. Collin, X.; Robert, J. M.; Wielgosz, G.; Le Baut, G.;
Bobin-Dubigeon, C.; Grimaud, N.; Petit, J. Y. Eur. J.
Med. Chem. 2001, 36, 639–649.
3. Trembly, B.; Slikker, J. N. Y. Acad. Sci. 1995, 765, 71–72.
4. Niwayama, S.; Turk, B. E.; Liu, J. O. J. Med. Chem. 1996,
39, 3044–3045.
5. Schreiber, S.; Nikolaus, S.; Hampe, J.; Homling, J.; Koop,
I.; Grossner, B.; Lochs, H.; Raedler, A. Lancet 1999, 353,
459–461.
6. Schwartz, T.; Lugert, E. In Pharmacology of the Skin;
Makart, H., Ed.; CRC: Boca Raton, FL, 1992; pp 283–313.
7. DÕAmbra, T. E.; Estep, K. G.; Bell, M. R.; Eissenstat, M.
A.; Josef, K. A.; Ward, S. J.; Haycock, D. A.; Baizman, E.
R.; Casiano, F. M.; Beglin, N. C.; Chippart, S. M.; Grego,
J. D.; Kulinig, R. K.; Daley, G. T. J. Med. Chem. 1992, 35,
124–135.
Compound
Topical application
inhibition % at 2 · 100lg
1
23
38
90
66
89
71
94
66
96
3
1
3
1
1
3
2
2
26
29
32
33
34
Dexamethasone
Ibuprofen
59 2.5
brought to the fore that the former were regularly more
efficacious. N-(Pyridin-3-ylmethyl)-3-[5-chloro-1-(4-
8. Hynes, J., Jr.; Leftheris, K.; Wu, H.; Pandit, C.; Chen, P.;
Norris, D. J.; Chen, B. C.; Zhao, R.; Kiener, P. A.; Chen,
X.; Turk, L. A.; Patil-Koota, V.; Gillooly, K. M.; Shuster,
D. J.; McIntyre, K. W. Bioorg. Med. Chem. Lett. 2002, 12,
2399–2402.
chlorobenzyl)-indol-3-yl]propanamide 32 constitutes
the most potent nonacidic NSAI compound ever discov-
ered in that series; its ID50 (24 13 lmol/kg) is compa-
rable with that of oxicam derivatives.20
9. Wrobleski, S. T.; Hynes, J., Jr.; Lin, S.; Norris, D. J.;
Pandit, C.; Spergel, S.; Wu, H.; Tokarski, J. S.; Chen, X.;
Kiener, P. A.; Chen, X.; Gillooly, K. M.; Kiener, P. A.;
McIntyre, K. W.; Patil-Koota, V.; Shuster, D. J.; Turk, L.
A. J. Med. Chem. 2003, 46, 2110–2116.
10. Breteche, A.; Duflos, M.; Dassonville, A.; Nourrisson, M.
R.; Brelet, J.; Le Baut, G.; Grimaud, N.; Petit, J. Y. J.
Enz. Inhib. Med. Chem. 2002, 17, 415–424.
11. Gallard, A.; Duflos, M.; Nourrisson, M. R.; Le Baut, G.;
Grimaud, N.; Petit, J. Y. J. Enz. Inhib. Med. Chem. 2003,
18, 201–208.
12. Allais, A.; Nomine, G. Ger. Patent 1,901,167, 1969; Chem.
Abstr. 1970, 72, 43440x.
Comparison of the inhibitory activity of (E)-propena-
mide 34 with that of the corresponding propanamide11
was in favour of the former: 80% at 0.1mmol/kg and
84% at 0.2mmol/kg. The level of activity of the N-(pyr-
idin-4-yl)propanamide 1 was maintained in 38, resulting
from the migration of the amidic chain from C-3 to N-1:
77% oedema inhibition; moreover, contrary to 1, no
toxic effect was observed at 0.1mmol/kg. These encour-
aging results warrant ongoing pharmacomodulation in
those two subseries.
The effect of the most active compounds, in the mouse
ear thickness reduction assay, was evaluated after topi-
cal application of 2 · 100lg/ear (Table 2). Although
propanamide 32 exhibited a significant inhibition per-
centage (71%), it was less efficacious in that test than
23, 29 and 33, which exerted an inhibition percentage
in the range of 90%.
13. Cooper, L. C.; Chicchi, C. G.; Dinnell, K.; Elliott, J. M.;
Hollingworth, G. J.; Kurtz, M. M.; Locker, K. L.;
Morrison, D.; Shaw, D. E.; Tsao, K. L.; Watt, A. P.;
Williams, A. R.; Swain, C. J. Bioorg. Med. Chem. Lett.
2001, 11, 1233–1236.
14. Alam, M. M.; Varala, R.; Adapa, R. Tetrahedron Lett.
2003, 44, 5115–5119.
15. Phillips, R. R. In OrganicReactions ; Adams, R., Ed.; John
Wiley and sons: New York, 1959; Vol. 10, pp 143–178.
These preliminary results tend to confirm the favourable
incidence of a 4-chlorobenzyl grouping fixed at the ind-
olic nitrogen of the three subseries of 3-(indol-3-yl)prop-
anamides. Their level of activity, comparable with that
of dexamethasone, prompts us to investigate their inhib-
itory effect in the multiple TPA-induced model of
chronic inflammation.21
´
16. Schoepfer, J.; Fretz, H.; Gay, B.; Furet, P.; Garcıa-
Echeverrıa, C.; End, N.; Caravatti, G. Bioorg. Med. Chem.
Lett. 1999, 9, 221–226.
17. Hegedus, L. S.; Winton, P. M.; Varaprath, S. J. Org.
Chem. 1981, 46, 2215–2221.
´
18. Carlson, R. P.; OÕNeill-Davis, L.; Chang, J.; Lewis, A. J.
Agents Actions 1985, 7, 197–204.
19. Chang, J.; Blazek, E.; Skowronek, M.; Miranari, L.;
Carlson, R. P. Eur. J. Pharmacol. 1987, 142, 197–205.
20. Zinnes, H.; Sirca, J. C.; Lindo, N.; Schwarz, M.; Fabian, A.
C.; Shavel, J.; Kasulanis, C. F.; Genzer, J. D.; Lumanski,
C.; Dipasquale, G. J. Med. Chem. 1982, 25, 12–18.
21. Alfort, J. G.; Stanzey, P. L.; Todderud, G.; Tramposch,
K. M. Agents Actions 1992, 37, 260–267.
Acknowledgements
The expert technical assistance of C. Chauvet is very
much appreciated.